Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Co-Trimoxazole; TMP-SMZ

PreclinicalSmall molecule

JJohns Hopkins Bloomberg School of Public Health

Co-Trimoxazole; TMP-SMZ is one of 2 small molecule programs targeting Neonatal Infection. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neonatal InfectionCompleted

Neonatal InfectionPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Neonatal Infection

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Co-Trimoxazole; TMP-SMZ

JJohns Hopkins Bloomberg School of Public Health

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neonatal Infection1 trial

Etiology, Prevention and Treatment of Neonatal Infections in the Community

Completed·JJohns Hopkins Bloomberg School of Public Health·N/A·NCT00198627·16,359 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Co-Trimoxazole; TMP-SMZ. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Co-Trimoxazole; TMP-SMZ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Co-Trimoxazole; TMP-SMZ. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins Bloomberg School of Public Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJohns Hopkins Bloomberg School of Public Health

Related News